Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 66

Breast Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15
Breast Diseases 55 43 44 73
Abnormality of the Breast 29

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Breast Disease

About this section
MedlinePlus : 43 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and prostatitis, and has symptoms including exanthema, mastodynia and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Acetylcholine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include the breast, breast and lymph node, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 76 Breast diseases can be classified either with disorders of the integument, or disorders of the... more...

Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 31.2 ERBB2 PGR TP53
2 prostatitis 30.4 KLK3 TGFB1 TNF
3 ductal carcinoma in situ 29.2 ERBB2 ESR1 PGR TP53
4 insulin-like growth factor i 29.2 ESR1 IGF1 IGFBP3 PRL SHBG
5 endometriosis 28.8 ESR1 ESR2 PGR
6 breast ductal carcinoma 28.8 CTSD ERBB2 ESR1 PGR TP53
7 premenstrual tension 28.7 PGR PRL SHBG
8 sporadic breast cancer 28.4 ERBB2 ESR1 ESR2 PGR TP53
9 gynecomastia 28.1 ESR1 KLK3 PGR PRL SHBG
10 mammographic density 27.1 COMT CYP1A1 CYP1B1 ESR1 IGF1 IGFBP3
11 breast cancer 24.4 CTSD CYP1A1 CYP1B1 ERBB2 ESR1 ESR2
12 mastitis 11.1
13 diabetic mastopathy 11.1
14 submandibular gland cancer 11.0 KLK3 TP53
15 slipped capital femoral epiphysis 11.0 IGF1 IGFBP3
16 gallbladder squamous cell carcinoma 10.9 ERBB2 TP53
17 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
18 endometrial clear cell adenocarcinoma 10.9 CTSD ESR1 TP53
19 atrophy of prostate 10.9 KLK3 TP53
20 secondary adrenal insufficiency 10.8 IGF1 IGFBP3
21 multiple fibroadenomas of the breast 10.8
22 hidradenocarcinoma 10.8 ERBB2 ESR1 TP53
23 galactorrhea 10.8 IGF1 PRL PRLR
24 pituitary infarct 10.7 IGF1 PRL
25 colorectal adenoma 10.7 IGF1 IGFBP3 TP53
26 47, xxy 10.7 IGFBP3 SHBG
27 bone resorption disease 10.7 ESR1 ESR2 IGF1
28 cervical adenocarcinoma 10.7 ERBB2 ESR1 TP53
29 central nervous system organ benign neoplasm 10.7 IGF1 PRL TP53
30 pituitary adenoma 1, multiple types 10.7 IGF1 IGFBP3 PRL
31 chromophobe adenoma 10.7 PRL PRLR TP53
32 hyperpituitarism 10.7 IGF1 IGFBP3 PRL
33 breast abscess 10.7
34 granulosa cell tumor of the ovary 10.6 ERBB2 PRL TP53
35 endocrine gland cancer 10.6 ESR1 IGFBP3 TP53
36 cell type benign neoplasm 10.6 IGF1 PRL TP53
37 comedo carcinoma 10.6 ERBB2 ESR1
38 lobular neoplasia 10.6 ERBB2 ESR1 ESR2 PRLR
39 uterine corpus serous adenocarcinoma 10.6 ERBB2 TP53
40 hypopituitarism 10.6 IGF1 IGFBP3 PRL
41 endometriosis of uterus 10.6 PRL PRLR
42 postpartum depression 10.5 COMT ESR1 PRL
43 oral cavity cancer 10.5 CYP1A1 ERBB2 TP53
44 recessive dystrophic epidermolysis bullosa 10.5 IGFBP3 TGFB1 TP53
45 respiratory system cancer 10.5 CYP1A1 ERBB2 TP53
46 turner syndrome 10.5 IGF1 IGFBP3 SHBG
47 androgenic alopecia 10.5 KLK3 PRL SHBG
48 sexual disorder 10.5 KLK3 PRL SHBG
49 anovulation 10.5 IGF1 PRL SHBG
50 acanthosis nigricans 10.4 IGF1 PRL SHBG

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


exanthema, mastodynia, pelvic pain, pruritus, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

GenomeRNAi Phenotypes related to Breast Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 ERBB2 IGF1 TGFB1
2 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1
3 Decreased viability with paclitaxel GR00179-A-3 9.02 TGFB1

MGI Mouse Phenotypes related to Breast Disease:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 CTSD ESR1 CYP1A1 CYP1B1 COMT ERBB2
2 behavior/neurological MP:0005386 10.43 CTSD ESR1 COMT ERBB2 ESR2 IGFBP3
3 endocrine/exocrine gland MP:0005379 10.42 CTSD ESR1 CYP1A1 COMT ERBB2 ESR2
4 cellular MP:0005384 10.38 ERBB2 CTSD IGF1 ESR2 ESR1 RHOC
5 cardiovascular system MP:0005385 10.35 ERBB2 CYP1A1 ESR1 COMT IGF1 ESR2
6 growth/size/body region MP:0005378 10.35 ERBB2 CTSD CYP1A1 IGF1 ESR2 IGFBP3
7 immune system MP:0005387 10.34 CTSD CYP1A1 ESR1 COMT ESR2 IGF1
8 integument MP:0010771 10.32 CTSD ESR1 ERBB2 ESR2 IGFBP3 IGF1
9 hematopoietic system MP:0005397 10.3 COMT CTSD CYP1A1 IGF1 ESR2 ESR1
10 adipose tissue MP:0005375 10.29 ESR1 ESR2 IGFBP3 IGF1 SOD2 PRLR
11 neoplasm MP:0002006 10.18 ESR1 CYP1B1 ERBB2 ESR2 IGF1 RHOC
12 embryo MP:0005380 10.16 COMT ERBB2 ESR1 PGR PRLR TGFB1
13 liver/biliary system MP:0005370 10.13 CYP1A1 ESR1 ESR2 IGFBP3 SOD2 PRL
14 limbs/digits/tail MP:0005371 10.11 ESR1 ERBB2 ESR2 IGFBP3 IGF1 PRLR
15 muscle MP:0005369 10.1 ERBB2 ESR1 ESR2 IGFBP3 IGF1 PGR
16 nervous system MP:0003631 10.1 COMT ERBB2 CTSD IGF1 ESR2 ESR1
17 reproductive system MP:0005389 9.97 ESR1 COMT ERBB2 ESR2 IGF1 SOD2
18 renal/urinary system MP:0005367 9.86 COMT IGF1 ESR2 ESR1 SOD2 IGFBP3
19 respiratory system MP:0005388 9.61 ERBB2 COMT IGF1 ESR2 IGFBP3 ESR1
20 skeleton MP:0005390 9.32 ERBB2 IGF1 ESR2 IGFBP3 ESR1 PGR
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 961)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3 51-84-3 187
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
5
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7439-89-6 23925
6
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 9552079 2713
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
8
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
9
Povidone Approved Phase 4,Phase 2 9003-39-8
10
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 498142 38904
12
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
14
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
15
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
16
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
17
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
18
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
22
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
23
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
24
Exemestane Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 5284616 6436030 46835353
27
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
28
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
29
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
30
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
31
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 180288-69-1 9903
32
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 104741 17756771
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
34
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
35
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 865-21-4 13342 241903
36
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 71486-22-1 60780 44424639
37
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
38
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 2078-54-8 4943
39
Palbociclib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 571190-30-2 11431660 5005498 5330286
40
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-23-7 5754
41
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-61-7 60961
42
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
43 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
44
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
45
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
46
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 60-00-4, 62-33-9 6049
47
Pentetic acid Approved Phase 4,Phase 3,Early Phase 1 67-43-6
48
Pamidronate Approved Phase 4,Phase 3,Phase 2 40391-99-9 4674
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
50
Ropivacaine Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 84057-95-4 71273 175805

Interventional clinical trials:

(show top 50) (show all 6590)
# Name Status NCT ID Phase Drugs
1 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
2 Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
3 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
4 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
5 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
6 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
7 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
8 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
9 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
10 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
11 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
12 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
13 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
14 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
15 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
16 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
17 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
18 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
19 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
20 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
21 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
22 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
23 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
24 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial Completed NCT03024697 Phase 4
25 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
26 Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
27 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
28 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
29 Sentinel Lymph Node Mapping Post-Injection Site Pain Completed NCT02065232 Phase 4 Tilmanocept;Sulfur Colloid
30 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4 Eribulin mesylate
31 Influence of Exceptional Patient Characteristics on Everolimus Exposure Completed NCT01948960 Phase 4 everolimus dose escalation
32 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
33 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
34 An Open-label, Multi-center Phase â…£ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
35 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Completed NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
36 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4 Tamoxifen,;Exemestane;Anastrozole;Letrozole
37 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
38 Wound Infiltration and Breast Cancer Surgery Completed NCT01404377 Phase 4
39 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed NCT01301729 Phase 4 Docetaxel;Paclitaxel;Trastuzumab
40 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
41 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4 5-FU（intravenous infusion）+epirubicin+cyclophosphamide;5-FU（intravenous bolus）+epirubicin+cyclophosphamide;epirubicin+cyclophosphamide
42 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Completed NCT01127295 Phase 4 Tamoxifen, Letrozole, Anastrozole or Exemestane
43 A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer Completed NCT01094184 Phase 4 Bevacizumab;Paclitaxel;Docetaxel
44 Post Market Study Using the Xoft Axxent System Completed NCT01017549 Phase 4
45 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
46 Use of the Conturaâ„¢ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients Completed NCT00882596 Phase 4
47 Use of the Conturaâ„¢ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients Completed NCT00882089 Phase 4
48 Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery Completed NCT00768222 Phase 4
49 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed NCT00688909 Phase 4 letrozole
50 A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer Completed NCT00649090 Phase 4 exemestane

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section

Genetic tests related to Breast Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Breast 29
Sources

Anatomical Context for Breast Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

19
The Breast

MalaCards organs/tissues related to Breast Disease:

41
Breast, Lymph Node, Bone, Brain, Testes, Lung, Prostate
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 625)
# Title Authors Year
1
Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain. ( 29517151 )
2018
2
Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. ( 29167285 )
2018
3
Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely<sup>Ar</sup> Campaign. ( 29968026 )
2018
4
Infectious and Inflammatory Breast Disease. ( 29298955 )
2018
5
Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease. ( 29599377 )
2018
6
Modern Approaches to the Surgical Management of Malignant Breast Disease: The Role of Breast Conservation, Complete Mastectomy, Skin- and Nipple-Sparing Mastectomy. ( 29080650 )
2018
7
Efficiency of Imaging Modalities in Male Breast Disease: Can Ultrasound Give Additional Information for Assessment of Gynecomastia Evolution? ( 29322116 )
2018
8
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. ( 29453232 )
2018
9
Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol. ( 29398746 )
2018
10
Ultrasonographic and Mammographic Findings of Male Breast Disease. ( 29708282 )
2018
11
Evaluation of 2 breast cancer risk models in a benign breast disease cohort. ( 29932456 )
2018
12
Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 29644560 )
2018
13
The Effects of <i>Berberis Vulgaris</i> Juice on Insulin Indices in Women with Benign Breast Disease: A Randomized Controlled Clinical Trial. ( 29796035 )
2018
14
Ethical Considerations of Medical Photography in the Management of Breast Disease. ( 29978370 )
2018
15
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer. ( 29872146 )
2018
16
Refining Risk Assessment in Women With Benign Breast Disease: An Ongoing Dilemma. ( 28376199 )
2017
17
Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. ( 28761938 )
2017
18
Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. ( 28643020 )
2017
19
Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. ( 27933411 )
2017
20
Benign breast disease and risk of thyroid cancer. ( 28681104 )
2017
21
Cowden Syndrome: Serendipitous Diagnosis in Patients with Significant Breast Disease. Case Series and Literature Review. ( 27886412 )
2017
22
Diabetic Mastopathy: A Systematic Review of Surgical Management of a Rare Breast Disease. ( 28272124 )
2017
23
Sexual function, anxiety and depression in women with benign breast disease. A case-control study. ( 29267489 )
2017
24
Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer. ( 29266172 )
2017
25
Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients. ( 28978076 )
2017
26
Breast disease in men in metropolitan SALo Paulo - Brazil. ( 28741872 )
2017
27
Association between mammographic breast density and histologic features of benign breast disease. ( 29258587 )
2017
28
Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 28846009 )
2017
29
Breast cancer screening: updated recommendations of the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian Federation of Gynecological and Obstetrical Associations. ( 28894332 )
2017
30
Body size from birth through adolescence in relation to risk of benign breast disease in young women. ( 28062981 )
2017
31
Fibromatosis, a benign breast disease mimicking carcinoma. A case report. ( 29545999 )
2017
32
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. ( 28736315 )
2017
33
Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening. ( 28427083 )
2017
34
Breast Disease Treatment in a US Military Hospital in Afghanistan. ( 27696612 )
2017
35
Evidence and role of phlebitis and lipid infiltration in the onset and pathogenesis of Wooden Breast Disease in modern broiler chickens. ( 28609139 )
2017
36
Cavernous sinus syndrome as the first manifestation of metastatic breast disease. ( 28480103 )
2017
37
Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. ( 28143431 )
2017
38
Breast Cancer Screening: Updated Recommendations of the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian Federation of Gynecological and Obstetrical Associations. ( 29036752 )
2017
39
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study. ( 28190250 )
2017
40
Breast fibromatosis, an unusual breast disease. ( 29302307 )
2017
41
Paget's Breast Disease: A Case Report and Review of the Literature. ( 29109950 )
2017
42
A prospective study of breast anthropomorphic measurements, volume and ptosis in 605 Asian patients with breast cancer or benign breast disease. ( 28192525 )
2017
43
Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. ( 27293993 )
2016
44
Assessing the Relationship of Mammographic Breast Density and Proliferative Breast Disease. ( 27261096 )
2016
45
Inflammatory breast disease: A pictorial essay with radiological-pathological correlation. ( 27324090 )
2016
46
Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer. ( 28006062 )
2016
47
Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. ( 27488681 )
2016
48
Phyllodes Tumor of the Breast: 307 Treated Cases, the Largest Mexican Experience at a Single Breast Disease Institution. ( 28855932 )
2016
49
Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. ( 26893016 )
2016
50
Breast Disease. Management and Therapies. ( 27466592 )
2016
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 64
Show member pathways
 13.45 ERBB2 IGF1 PRL PRLR STAT5A TGFB1
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.32 ERBB2 PRL PRLR STAT5A TGFB1 TNF
3
Circadian entrainment 37
Show member pathways
 12.98 COMT CTSD ESR1 ESR2 PGR TGFB1
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.93 ERBB2 IGF1 PRL PRLR TNF TP53
5
Endometrial cancer 37
Show member pathways
 12.8 ERBB2 IGF1 KLK3 STAT5A TGFB1 TP53
6
ErbB4 Pathway 64
Show member pathways
 12.74 ERBB2 IGF1 PRL PRLR STAT5A
7
MAPK signaling pathway 1 37
12.72 ERBB2 IGF1 TGFB1 TNF TP53
8
Glioma 37
Show member pathways
 12.64 ERBB2 ESR1 ESR2 IGF1 STAT5A TP53
9
Gastric cancer 37
Show member pathways
 12.53 ERBB2 ESR1 ESR2 IGF1 PGR TGFB1
10
Pathways in cancer 37
12.48 ERBB2 ESR1 ESR2 IGF1 KLK3 STAT5A
11
HTLV-I infection 37
12.38 STAT5A TGFB1 TNF TP53
12
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.27 ERBB2 ESR1 ESR2 IGF1
13
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.06 ERBB2 IGF1 KLK3 TGFB1
14
Proteoglycans in cancer 37
12.04 ERBB2 ESR1 IGF1 TGFB1 TNF TP53
15
Prolactin Signaling Pathway 1 37
Show member pathways
 11.95 CTSD ERBB2 ESR1 ESR2 PRL PRLR
16
Spinal Cord Injury 1
11.94 RHOC TGFB1 TNF TP53
17
DNA Damage Response (only ATM dependent) 1
11.9 ERBB2 SOD2 TGFB1 TP53
18
Adipogenesis 1
11.89 IGF1 PRLR STAT5A TGFB1 TNF
19
Senescence and Autophagy in Cancer 1
11.84 IGF1 IGFBP3 TGFB1 TP53
20
Nuclear Receptor transcription pathway 66
Show member pathways
 11.8 ESR1 ESR2 PGR
21
Glucocorticoid receptor regulatory network 1
11.75 PRL STAT5A TP53
22
Steroid hormone biosynthesis 37
Show member pathways
 11.63 COMT CYP1A1 CYP1B1
23
Lung fibrosis 1
11.61 IGF1 TGFB1 TNF
24
Signaling events mediated by PTP1B 1
11.5 PRL PRLR STAT5A
25
Ovarian steroidogenesis 37
11.48 CYP1A1 CYP1B1 IGF1
26
Aryl Hydrocarbon Receptor 1
11.42 CYP1A1 CYP1B1 ESR1 TNF
27
LKB1 signaling events 1
11.4 CTSD ESR1 TP53
28
Aryl Hydrocarbon Receptor Pathway 1
11.39 CYP1A1 CYP1B1 TGFB1 TNF
29
Growth hormone receptor signaling 66
Show member pathways
 11.38 PRL PRLR STAT5A
30
Estrogen metabolism 1
Show member pathways
 11.27 COMT CYP1A1 CYP1B1
31
Ovarian Infertility Genes 1
11.23 ESR2 PGR PRLR
32
Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 22
11.15 ESR1 ESR2 SOD2
33
Signaling by ERBB4 66
Show member pathways
 11.13 ERBB2 ESR1 PGR PRL PRLR STAT5A
34
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.98 IGF1 IGFBP3 KLK3
35
Estrogen Receptor Pathway 1
10.75 CYP1A1 CYP1B1 ESR1
36
EV release from cardiac cells and their functional effects 1
10.61 PRL TNF
37
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 61
10.19 ESR1 ESR2
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CTSD ESR2 IGF1 IGFBP3 KLK3 PRL
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 ERBB2 IGF1 TGFB1 TNF TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.93 ESR1 ESR2 IGF1 TGFB1 TNF TP53
3 negative regulation of gene expression GO:0010629 9.91 ESR1 PGR TGFB1 TNF
4 cellular protein metabolic process GO:0044267 9.91 IGF1 IGFBP3 KLK3 PRL
5 positive regulation of apoptotic process GO:0043065 9.91 CYP1B1 IGFBP3 TGFB1 TNF TP53
6 positive regulation of protein kinase B signaling GO:0051897 9.83 ERBB2 ESR1 TGFB1 TNF
7 female pregnancy GO:0007565 9.82 COMT PRL TGFB1
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 IGF1 TGFB1 TP53
9 positive regulation of MAP kinase activity GO:0043406 9.76 ERBB2 TGFB1 TNF
10 positive regulation of epithelial cell proliferation GO:0050679 9.75 ERBB2 IGF1 TGFB1
11 steroid hormone mediated signaling pathway GO:0043401 9.74 ESR1 ESR2 PGR
12 positive regulation of fibroblast proliferation GO:0048146 9.71 ESR1 IGF1 TGFB1
13 protein kinase B signaling GO:0043491 9.67 IGF1 TGFB1 TNF
14 lactation GO:0007595 9.65 PRL PRLR STAT5A
15 estrogen metabolic process GO:0008210 9.64 COMT CYP1B1
16 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.64 IGF1 IGFBP3
17 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.63 ESR1 TP53
18 cell proliferation GO:0008283 9.63 CYP1A1 ERBB2 IGF1 PRL TGFB1 TP53
19 positive regulation of histone deacetylation GO:0031065 9.62 TGFB1 TP53
20 omega-hydroxylase P450 pathway GO:0097267 9.62 CYP1A1 CYP1B1
21 response to organic substance GO:0010033 9.62 CYP1A1 IGF1 TGFB1 TNF
22 mammary gland development GO:0030879 9.61 PGR PRL TGFB1
23 toxin metabolic process GO:0009404 9.59 CYP1A1 CYP1B1
24 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.56 ESR1 TGFB1
25 regulation of multicellular organism growth GO:0040014 9.54 IGF1 PRL STAT5A
26 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.43 PRL TGFB1 TP53
27 positive regulation of mononuclear cell migration GO:0071677 9.4 TGFB1 TNF
28 cellular response to organic cyclic compound GO:0071407 9.26 CYP1A1 CYP1B1 TGFB1 TNF
29 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.8 PRL PRLR STAT5A
30 negative regulation of cell proliferation GO:0008285 10 CYP1B1 IGFBP3 SOD2 TGFB1 TP53

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 ERBB2 ESR1 ESR